Verastem (VSTM) EV/FCF: History & Chart

Verastem, Inc.(VSTM)

Biotechnology · Needham, MA

$7.75-0.25 (-3.13%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Verastem, Inc.

Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.

Needham, MA

102 employees

www.verastem.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Daniel W. Paterson

View full financials

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Verastem, Inc. (VSTM)	$681.02M	N/A	N/A	N/A	N/A
Solid Biosciences Inc. (SLDB)vs ›	$681.27M	N/A	N/A	N/A	N/A
Anteris Technologies Global Corp. (AVR)vs ›	$685.49M	N/A	N/A	N/A	N/A
MiMedx Group, Inc. (MDXG)vs ›	$673.41M	13.29x	10.66x	30.61x	30.61x
Olema Pharmaceuticals, Inc. (OLMA)vs ›	$691.79M	N/A	N/A	N/A	N/A
Faeth Therapeutics, Inc. (FTH)vs ›	$693.19M	N/A	N/A	N/A	N/A
Wave Life Sciences Ltd. (WVE)vs ›	$693.61M	N/A	N/A	N/A	N/A
Cytek Biosciences, Inc. (CTKB)vs ›	$694.79M	N/A	26.28x	227.60x	393.69x
Helus Pharma Inc. (HELP)vs ›	$666.95M	N/A	N/A	N/A	N/A
Annexon, Inc. (ANNX)vs ›	$660.29M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/FCF RATIO

TTM

Verastem, Inc. (VSTM)

$681.02M

N/A

Solid Biosciences Inc. (SLDB)vs ›

$681.27M

N/A

Anteris Technologies Global Corp. (AVR)vs ›

$685.49M